Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Metastasis | Research article

The role of clonal communication and heterogeneity in breast cancer

Authors: Ana Martín-Pardillos, Ángeles Valls Chiva, Gemma Bande Vargas, Pablo Hurtado Blanco, Roberto Piñeiro Cid, Pedro J. Guijarro, Stefan Hümmer, Eva Bejar Serrano, Aitor Rodriguez-Casanova, Ángel Diaz-Lagares, Josep Castellvi, Samuel Miravet-Verde, Luis Serrano, María Lluch-Senar, Víctor Sebastian, Ana Bribian, Laura López-Mascaraque, Rafael López-López, Santiago Ramón y Cajal

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Cancer is a rapidly evolving, multifactorial disease that accumulates numerous genetic and epigenetic alterations. This results in molecular and phenotypic heterogeneity within the tumor, the complexity of which is further amplified through specific interactions between cancer cells. We aimed to dissect the molecular mechanisms underlying the cooperation between different clones.

Methods

We produced clonal cell lines derived from the MDA-MB-231 breast cancer cell line, using the UbC-StarTrack system, which allowed tracking of multiple clones by color: GFP C3, mKO E10 and Sapphire D7. Characterization of these clones was performed by growth rate, cell metabolic activity, wound healing, invasion assays and genetic and epigenetic arrays. Tumorigenicity was tested by orthotopic and intravenous injections. Clonal cooperation was evaluated by medium complementation, co-culture and co-injection assays.

Results

Characterization of these clones in vitro revealed clear genetic and epigenetic differences that affected growth rate, cell metabolic activity, morphology and cytokine expression among cell lines. In vivo, all clonal cell lines were able to form tumors; however, injection of an equal mix of the different clones led to tumors with very few mKO E10 cells. Additionally, the mKO E10 clonal cell line showed a significant inability to form lung metastases. These results confirm that even in stable cell lines heterogeneity is present. In vitro, the complementation of growth medium with medium or exosomes from parental or clonal cell lines increased the growth rate of the other clones. Complementation assays, co-growth and co-injection of mKO E10 and GFP C3 clonal cell lines increased the efficiency of invasion and migration.

Conclusions

These findings support a model where interplay between clones confers aggressiveness, and which may allow identification of the factors involved in cellular communication that could play a role in clonal cooperation and thus represent new targets for preventing tumor progression.
Appendix
Available only for authorised users
Literature
1.
2.
DeVita VT, Lawrence TS, Rosenberg SA, DePinho RA, Devita WRA. Hellman, and Rosenberg's cancer: principles & practice of oncology. 10th ed. Philadephia: Lippincott Williams and Wilkins; 2014.
3.
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006;355(6):560–9.PubMedCrossRef
4.
Gerlinger M, Horswell S, Larkin J, Rowan AJ, Salm MP, Varela I, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet. 2014;46(3):225–33.PubMedPubMedCentralCrossRef
5.
Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883–92.PubMedPubMedCentralCrossRef
6.
Nash I. Intratumor heterogeneity and branched evolution. N Engl J Med. 2012;366(22):2132–3 discussion 3.PubMedCrossRef
7.
8.
Hiley CT, Swanton C. Spatial and temporal cancer evolution: causes and consequences of tumour diversity. Clin Med. 2014;14(Suppl 6):s33–7.CrossRef
9.
10.
Lloyd MC, Cunningham JJ, Bui MM, Gillies RJ, Brown JS, Gatenby RA. Darwinian dynamics of Intratumoral heterogeneity: not solely random mutations but also variable environmental selection forces. Cancer Res. 2016;76(11):3136–44.PubMedPubMedCentralCrossRef
11.
Heppner GYK, Miller B, Miller F. Tumor heterogeneity in metastasis. Prog Clin Biol Res. 1986;212:45–59.
12.
Heppner GH, Shekhar M. Tumor heterogeneity is fundamental to the tumor ecosystem. Oncology (Williston Park). 2014;28(9):780–1.
13.
Gatenby RA, Cunningham JJ, Brown JS. Evolutionary triage governs fitness in driver and passenger mutations and suggests targeting never mutations. Nat Commun. 2014;5:5499.PubMedCrossRef
14.
Alderton GK. Tumour evolution: epigenetic and genetic heterogeneity in metastasis. Nat Rev Cancer. 2017;17(3):141.PubMedCrossRef
15.
Almendro V, Kim HJ, Cheng YK, Gonen M, Itzkovitz S, Argani P, et al. Genetic and phenotypic diversity in breast tumor metastases. Cancer Res. 2014;74(5):1338–48.PubMedPubMedCentralCrossRef
16.
Denisov EV, Litviakov NV, Zavyalova MV, Perelmuter VM, Vtorushin SV, Tsyganov MM, et al. Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression. Sci Rep. 2014;4:4709.PubMedPubMedCentralCrossRef
17.
Russo M, Siravegna G, Blaszkowsky LS, Corti G, Crisafulli G, Ahronian LG, et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal Cancer. Cancer Discov. 2016;6(2):147–53.PubMedCrossRef
18.
19.
20.
21.
Ramon Y Cajal S, Capdevila C, Hernandez-Losa J, De Mattos-Arruda L, Ghosh A, Lorent J, et al. Cancer as an ecomolecular disease and a neoplastic consortium. Biochim Biophys Acta. 2017;1868(2):484–99.
22.
23.
Bertolaso M. Philosophy of cancer: a dynamic and relational view. New York: Springer; 2016.
24.
Chapman A, Fernandez del Ama L, Ferguson J, Kamarashev J, Wellbrock C, Hurlstone A. Heterogeneous tumor subpopulations cooperate to drive invasion. Cell Rep. 2014;8(3):688–95.PubMedPubMedCentralCrossRef
25.
Aceto N, Bardia A, Miyamoto DT, Donaldson MC, Wittner BS, Spencer JA, et al. Circulating tumor cell clusters are oligoclonal precursors of breast cancer metastasis. Cell. 2014;158(5):1110–22.PubMedPubMedCentralCrossRef
26.
Zhao Q, Eichten A, Parveen A, Adler C, Huang Y, Wang W, et al. Single-cell transcriptome analyses reveal endothelial cell heterogeneity in tumors and changes following antiangiogenic treatment. Cancer Res. 2018;78(9):2370–82.PubMedCrossRef
27.
28.
Ramon Y Cajal S, Castellvi J, Hummer S, Peg V, Pelletier J, Sonenberg N. Beyond molecular tumor heterogeneity: protein synthesis takes control. Oncogene. 2018;37(19):2490–501.PubMedPubMedCentralCrossRef
29.
Nguyen A, Yoshida M, Goodarzi H, Tavazoie SF. Highly variable cancer subpopulations that exhibit enhanced transcriptome variability and metastatic fitness. Nat Commun. 2016;7:11246.PubMedPubMedCentralCrossRef
30.
Zhou H, Neelakantan D, Ford HL. Clonal cooperativity in heterogenous cancers. Semin Cell Dev Biol. 2017;64:79–89.PubMedCrossRef
31.
Uhlen M, Zhang C, Lee S, Sjostedt E, Fagerberg L, Bidkhori G, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352).PubMedCrossRef
32.
McDonald OG, Li X, Saunders T, Tryggvadottir R, Mentch SJ, Warmoes MO, et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat Genet. 2017;49(3):367–76.PubMedPubMedCentralCrossRef
33.
34.
Ramon Y Cajal S, De Mattos-Arruda L, Sonenberg N, Cortes J, Peg V. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets. Clin Transl Oncol. 2014;16(11):937–41.PubMedCrossRef
35.
Yusa K, Rad R, Takeda J, Bradley A. Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon. Nat Methods. 2009;6(5):363–9.PubMedPubMedCentralCrossRef
36.
37.
Genomes Project C, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74 Epub 2015/10/04.CrossRef
38.
39.
40.
41.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249–64.CrossRefPubMed
42.
Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.PubMedCrossRef
43.
Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, et al. Validation of a DNA methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011;6(6):692–702.PubMedCrossRef
44.
Moran S, Arribas C, Esteller M. Validation of a DNA methylation microarray for 850,000 CpG sites of the human genome enriched in enhancer sequences. Epigenomics. 2016;8(3):389–99.PubMedCrossRef
45.
Amaro A, Angelini G, Mirisola V, Esposito AI, Reverberi D, Matis S, et al. A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicity in vivo. Oncotarget. 2016;7(42):68803–20.PubMedPubMedCentralCrossRef
46.
Garcia-Marques J, Lopez-Mascaraque L. Clonal identity determines astrocyte cortical heterogeneity. Cereb Cortex. 2013;23(6):1463–72.PubMedCrossRef
47.
Bribian A, Figueres-Onate M, Martin-Lopez E, Lopez-Mascaraque L. Decoding astrocyte heterogeneity: new tools for clonal analysis. Neuroscience. 2016;323:10–9.PubMedCrossRef
48.
Grada A, Otero-Vinas M, Prieto-Castrillo F, Obagi Z, Falanga V. Research techniques made simple: analysis of collective cell migration using the wound healing assay. J Invest Dermatol. 2017;137(2):e11–e6.PubMedCrossRef
49.
Xie F, Ling L, van Dam H, Zhou F, Zhang L. TGF-beta signaling in cancer metastasis. Acta Biochim Biophys Sin. 2018;50(1):121–32.PubMedCrossRef
50.
51.
Hutchinson L. Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol. 2010;7(12):669–70.PubMedCrossRef
52.
Khan GN, Kim EJ, Shin TS, Lee SH. Heterogeneous cell types in single-cell-derived clones of MCF7 and MDA-MB-231 cells. Anticancer Res. 2017;37(5):2343–54.PubMedCrossRef
53.
54.
Aleskandarany MA, Vandenberghe ME, Marchio C, Ellis IO, Sapino A, Rakha EA. Tumour heterogeneity of breast Cancer: from morphology to personalised medicine. Pathobiology. 2018;85(1–2):23–34.PubMedCrossRef
55.
Talmadge JE, Fidler IJ. Cancer metastasis is selective or random depending on the parent tumour population. Nature. 1982;297(5867):593–4.PubMedCrossRef
56.
57.
58.
Cheung KJ, Padmanaban V, Silvestri V, Schipper K, Cohen JD, Fairchild AN, et al. Polyclonal breast cancer metastases arise from collective dissemination of keratin 14-expressing tumor cell clusters. Proc Natl Acad Sci U S A. 2016;113(7):E854–63.PubMedPubMedCentralCrossRef
59.
60.
61.
Curtius K, Wright NA, Graham TA. An evolutionary perspective on field cancerization. Nat Rev Cancer. 2018;18(1):19–32.PubMedCrossRef
62.
Michor F, Polyak K. The origins and implications of intratumor heterogeneity. Cancer Prev Res. 2010;3(11):1361–4.CrossRef
63.
Parsons BL. Multiclonal tumor origin: evidence and implications. Mutat Res Rev Mutat Res. 2018;777:1–18.CrossRefPubMed
64.
65.
Gao R, Davis A, McDonald TO, Sei E, Shi X, Wang Y, et al. Punctuated copy number evolution and clonal stasis in triple-negative breast cancer. Nat Genet. 2016;48(10):1119–30.PubMedPubMedCentralCrossRef
66.
Kim C, Gao R, Sei E, Brandt R, Hartman J, Hatschek T, et al. Chemoresistance evolution in triple-negative breast Cancer delineated by single-cell sequencing. Cell. 2018;173(4):879–93 e13.PubMedPubMedCentralCrossRef
67.
Schlange T, Matsuda Y, Lienhard S, Huber A, Hynes NE. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation. Breast Cancer Res. 2007;9(5):R63.PubMedPubMedCentralCrossRef
68.
Lin C, Liao W, Jian Y, Peng Y, Zhang X, Ye L, et al. CGI-99 promotes breast cancer metastasis via autocrine interleukin-6 signaling. Oncogene. 2017;36(26):3695–705.PubMedCrossRef
69.
Feng Q, Zhang C, Lum D, Druso JE, Blank B, Wilson KF, et al. A class of extracellular vesicles from breast cancer cells activates VEGF receptors and tumour angiogenesis. Nat Commun. 2017;8:14450.PubMedPubMedCentralCrossRef
70.
71.
O'Brien K, Rani S, Corcoran C, Wallace R, Hughes L, Friel AM, et al. Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells. Eur J Cancer. 2013;49(8):1845–59 Epub 2013/03/05.PubMedCrossRef
Metadata
Title
The role of clonal communication and heterogeneity in breast cancer
Authors
Ana Martín-Pardillos
Ángeles Valls Chiva
Gemma Bande Vargas
Pablo Hurtado Blanco
Roberto Piñeiro Cid
Pedro J. Guijarro
Stefan Hümmer
Eva Bejar Serrano
Aitor Rodriguez-Casanova
Ángel Diaz-Lagares
Josep Castellvi
Samuel Miravet-Verde
Luis Serrano
María Lluch-Senar
Víctor Sebastian
Ana Bribian
Laura López-Mascaraque
Rafael López-López
Santiago Ramón y Cajal
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5883-y

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue

Research article

Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis

Research article

Feasibility of high intensity interval training in patients with breast Cancer undergoing anthracycline chemotherapy: a randomized pilot trial

Research article

Diagnostic accuracy of 13N-ammonia PET, 11C-methionine PET and 18F-fluorodeoxyglucose PET: a comparative study in patients with suspected cerebral glioma

Research article

Patient and carer perceived barriers to early presentation and diagnosis of lung cancer: a systematic review

Research article

Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer

Case report

Metastasis in penile corpus cavernosum from esophageal squamous carcinoma after curative resection: a case report
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits